Hisamitsu Pharmaceutical Co., Inc.
HTSUF
Other OTC29.00
USD
- -
- -
ISIN
JP3784600003
Return %
Stock
S&P500
1Y
-10.22
26.84
3Y
0.76
77.03
5Y
-52.46
80.55
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Kazuhide Nakatomi
- Full Time Employees
- 2,759
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 408, Tashiro Daikan-machi Tosu Japan 841-0017
- IPO Date
- Sep 23, 2010
- Website
- hisamitsu.co.jp
- Similar Companies
- Business
- Hisamitsu Pharmaceutical Co., Inc. Hisamitsu Pharmaceutical Co., Inc. (HTSUF) engages in the research, development, manufacture and marketing of transdermal drug delivery systems (TDDS), with a focus on topical pain relief patches and related pharmaceutical products. The company produces a broad portfolio of over-the-counter (OTC) external pain-relieving drugs under flagship brands including SALONPAS, NOBINOBI, SALONSIP, AIR SALONPAS and FEITAS; athlete's foot remedies such as BUTENALOCK; allergy sinus medications like ALLEGRA FX; quasi-drugs and cosmetics; as well as prescription transdermal patches such as MOHRUS TAPE and MOHRUS PAP XR for analgesic anti-inflammatory applications, female hormone patches, asthma treatment patches and overactive bladder treatments. Its products target consumers and healthcare providers seeking non-invasive drug delivery solutions for pain management, inflammation, hormonal therapy and other conditions, with exports spanning more than 40 countries across Asia, the United States, Europe, Brazil, Australia and other regions. Founded in 1847 and formally established in 1944, Hisamitsu Pharmaceutical maintains its primary headquarters at the Kyushu Head Office in Tosu, Saga Prefecture, Japan, alongside a Tokyo Head Office, multiple domestic branches and sales offices, the SAGA Global Research Center, and factories in Utsunomiya and Tosu. The company operates subsidiaries in Japan including Hisamitsu Wellness and overseas entities such as Hisamitsu America, Noven Pharmaceuticals in the United States, Hisamitsu Farmaceutica do Brasil, Hisamitsu UK and Hisamitsu Pharmaceutical in China, Vietnam, Malaysia, Indonesia, Hong Kong, Singapore, the Philippines and Taiwan. Approximately 2,759 consolidated employees support its operations as of early 2024, under President and CEO Kazuhide Nakatomi. Among its latest developments, Hisamitsu initiated clinical development of HP-3150, a transdermal nonsteroidal pain treatment, in the United States in October 2024 and announced Phase II results for HP-6050 in Japan in July 2024; completed construction of the new SAGA Global Research Center in March 2024; invested in ReEir, Inc., a regenerative medicine bio-venture, in December 2024; received adoption for AMED funding of new-generation vaccine R&D in November 2024; introduced an Employee Shareholding Incentive Plan (E-Ship) and expanded domestic distribution in 2024; acquired DX Certification from Japan's Ministry of Economy, Trade and Industry in May 2024; and pursued open innovation partnerships including with universities via the SAGA Global Research Center in October 2024. SALONPAS maintained its status as the world's No. 1 OTC topical analgesic patch brand for the eighth consecutive year as of May 2024, while the company continues treasury share repurchases and stock compensation initiatives into 2025.
Hisamitsu Shares Surge as Company Confirms ¥457 Billion Management Buyout
Japan's Hisamitsu Pharmaceutical plans $2.55 billion MBO